{"id":"NCT02707601","sponsor":"Gilead Sciences","briefTitle":"Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment","officialTitle":"A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment, the HIV/HCV Co-STARs Study (Co-infection Treatment With Single Tablet Antiviral Regimens)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-01","primaryCompletion":"2017-09-14","completion":"2017-09-29","firstPosted":"2016-03-14","resultsPosted":"2018-10-09","lastUpdate":"2018-11-14"},"enrollment":150,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1 Infection","HCV Infection"],"interventions":[{"type":"DRUG","name":"E/C/F/TAF","otherNames":["Genvoya®"]},{"type":"DRUG","name":"F/R/TAF","otherNames":["Odefsey®"]},{"type":"DRUG","name":"LDV/SOF","otherNames":["Harvoni®","GS-5885/GS-7977"]}],"arms":[{"label":"E/C/F/TAF + LDV/SOF","type":"EXPERIMENTAL"},{"label":"F/R/TAF + LDV/SOF","type":"EXPERIMENTAL"}],"summary":"This study will evaluate efficacy of ledipasvir/sofosbuvir (LDV/SOF) and safety and tolerability of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or emtricitabine/rilpivirine/tenofovir alafenamide (F/R/TAF) from the current antiretroviral (ARV) therapy and in virologically-suppressed, HIV-1/HCV co-infected participants.","primaryOutcome":{"measure":"Percentage of Participants With HCV RNA < LLOQ at 12 Weeks After Discontinuation of LDV/SOF Treatment (SVR12)","timeFrame":"HCV Posttreatment Week 12","effectByArm":[{"arm":"E/C/F/TAF + LDV/SOF","deltaMin":98.6,"sd":null},{"arm":"F/R/TAF + LDV/SOF","deltaMin":95.8,"sd":null}],"pValues":[{"comp":"OG000","p":"0.002"},{"comp":"OG001","p":"0.042"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":null},"locations":{"siteCount":43,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["31995556"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":74},"commonTop":["Cough","Upper respiratory tract infection","Urinary tract infection","Arthralgia","Headache"]}}